

## Reclassification of class C shares to ordinary shares and transfer of ordinary shares within the framework of a long-term incentive plan

Uppsala, Sweden – July 17, 2024 – The Annual General Meeting of Biotage AB (publ) ("Biotage") resolved on April 28, 2021 to adopt a long-term incentive plan ("LTIP 2021") which has now expired and for this reason, a total of 31,628 ordinary shares are transferred free of charge to the participants in LTIP 2021. To cover tax costs associated with LTIP 2021, some participants intend to sell a number of shares through Danske Bank A/S on Nasdaq Stockholm and, correspondingly, the company transfers a maximum of 9,459 ordinary shares to cover social contribution costs associated with LTIP 2021 which is expected to take place during the period July 18, 2024 until July 24, 2024, at a price within the registered price range at the relevant time. In order to enable the transfer of own ordinary shares, the Board of Directors has resolved to reclassify 41,087 class C shares into 41,087 ordinary shares in accordance with the reclassification provision in the company's Articles of Association.

The company's holding of own class C shares previously amounted to 659,510. Following the conversion of 41,087 class C shares and transfer of the corresponding number of ordinary shares, Biotage will hold 618,423 own class C shares.

## **Contacts**

Torben Jörgensen, Interim President & CEO Tel: +46-707 49 05 84, torben.jorgensen@biotage.com

## **About Biotage**

Biotage is the Global Go-To Separations Company, supporting customers from drug discovery and development through to diagnostics and analytical testing with intelligent and sustainable workflow solutions. Our expertise and top-tier separation solutions play a key role in streamlining our customers' workflows and improving their outcomes.

Headquartered in Sweden, Biotage operates globally with 700 employees, serving over 80 countries. Our company is listed on NASDAQ Stockholm (BIOT). Website: www.biotage.com



This information is information that Biotage is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2024-07-31 17:30 CEST.

## **Attachments**

Reclassification of class C shares to ordinary shares and transfer of ordinary shares within the framework of a long-term incentive plan